This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Scientific Reports Open Access 26 April 2022
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bekassy AN, Hermans J, Gorin NC, Gratwohl A . Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996; 17: 801–808.
Berthou C, Leglise MC, Herry A, Balcon D, Hardy E, Lessard M et al. Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia. Leukemia 1998; 12: 1676–1681.
Cunningham I . Extramedullary sites of leukemia relapse after transplant. Leuk Lymphoma 2006; 47: 1754–1767.
Frassoni F, Barrett AJ, Granena A, Ernst P, Garthon G, Kolb HJ et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol 1988; 70: 317–320.
Koc Y, Miller KB, Schenkein DP, Daoust P, Sprague K, Berkman E . Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer 1999; 85: 608–615.
Lee KH, Lee JH, Choi SJ, Kim S, Seol M, Lee YS et al. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant 2003; 32: 835–842.
Savani BN, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K . Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 2009; 44: 769–777.
de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010; 116: 5420–5431.
Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26: 381–389.
Serrao A, Loglisci G, Salaroli A, Zacheo I, Alimena G, Breccia M . Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization. Leuk Lymphoma, (e-pub ahead of print 9 July 2012).
The authors declare no conflict of interest.
About this article
Cite this article
Antar, A., Otrock, Z., Kharfan-Dabaja, M. et al. Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 48, 994–995 (2013). https://doi.org/10.1038/bmt.2012.256
This article is cited by
Scientific Reports (2022)
Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation
International Journal of Hematology (2018)